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take a systematic approach to managing patients whom 
they suspect of having treatment-refractory hypothyroid-
ism. This may include searching for, and adjusting, occult 
medical conditions and/or other factors that may affect the 
absorption of levothyroxine, before up-titrating the dose of 
traditional levothyroxine therapy. Depending on the under-
lying pathology, another approach that may be considered 
is to try alternative formulations of levothyroxine that are 
less susceptible to intolerance issues related to excipients, 
or, in some cases, to malabsorption. The early discovery of 
these factors via a thoughtful patient work-up may avoid 
unnecessary thyroid medication adjustments and their con-
sequences for both patients and clinicians.
Keywords Hypothyroidism · Levothyroxine · 
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Introduction
Primary hypothyroidism is considered to be refractory to 
oral thyroxine when there is biochemical or clinical evi-
dence of hypothyroidism [serum level of thyroid-stimulat-
ing hormone (TSH) above the upper target level, usually 
4.5 mU/L following a 6-week interval after the dosage was 
last increased] and/or unresolved hypothyroid symptoms, 
despite increasing dosages of levothyroxine beyond 1.9 μg/
kg daily [1–3]. Further increments in the dosage of thyrox-
ine may not always be the most appropriate intervention as 
supratherapeutic doses have been associated with cardio-
vascular and other side effects. When confronted with cases 
in which unexpectedly high doses of thyroxine are required, 
clinicians should confirm compliance and search for causes 
of decreased absorption or increased demand for thyrox-
ine (Table 1) [3–8]. This consensus paper provides current 
Abstract There is a frequently encountered subset of 
hypothyroid patients who are refractory to standard thy-
roid hormone replacement treatment and require unexpect-
edly high doses of levothyroxine. In addition to clinical 
situations where hypothyroid patients are non-compliant, 
or where there is the possibility of excipient-induced dis-
ease exacerbation (gluten/celiac disease), therapeutic 
failure may be due to impaired absorption of the admin-
istered drug. The common approach to managing patients 
with unusual thyroxine needs is to escalate the dose of 
levothyroxine until targeted TSH levels are achieved. This 
approach can increase the risk for prolonged exposure to 
supratherapeutic doses of levothyroxine, which increase 
the chances of adverse outcomes. Repeated adjustments 
of levothyroxine can also escalate the costs of treatment, 
as frequent office visits and laboratory tests are required to 
determine and maintain the desired dose. Clinicians should 
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thinking on the causes of refractory hypothyroidism and 
recommendations for its diagnosis and management.
Background
Refractory hypothyroidism is a clinical condition that is 
increasingly recognized worldwide [8–10]. Even though its 
prevalence has not been precisely documented, non-optimal 
thyroxine therapy, as evidenced by TSH levels above (or 
below) the reference range, is common (Table 2) [11–17]. 
The most recent data supporting this finding were reported 
by Vaisman in a multicenter study from Brazil, in which 
28% of 2292 hypothyroid patients had elevated serum TSH 
levels with a background of thyroid hormone therapy [15]. 
Results from prior trials are consistent with this finding 
and are suggestive that a substantial percentage of patients 
may not achieve their TSH target when using levothyroxine 
[11–14]. Since levothyroxine is the first-line treatment for 
hypothyroidism [18, 19] and one of the most widely used 
drugs in the US with more than 115 million prescriptions 
dispensed in 2013 [20], a fresh examination of the causes 
of its frequent sub-optimal performance is warranted.
Refractory hypothyroidism—clinical 
and laboratory findings
Diagnosis of refractory hypothyroidism is both art and sci-
ence. The traditional diagnostic tools such as laboratory 
tests (TSH, free (F) T4, free (F) T3, and others) can indi-
cate thyroid dysfunction. However, it is not uncommon to 
discover symptoms of both hypo- and hyperthyroidism in 
the context of diagnostic findings that are within the desired 
reference range specified by the current treatment guide-
lines [18]. Supratherapeutic doses of levothyroxine, which 
can induce iatrogenic hyperthyroidism, should not be used 
as a strategy to suppress hypothyroidism symptoms. In the 
panel’s experience, such patients may be referred to a spe-
cialist for additional evaluation after having been initiated 
on unexpectedly high doses of levothyroxine (>1.9 µg/kg/
day) and continuing to experience persistent symptoms of 
hypothyroidism.
TSH testing
According to the most recent guidelines from the Ameri-
can Thyroid Association (ATA), “TSH is the most reliable 
marker of adequacy of replacement treatment, and a value 
within the reference range (0.4–4.0 mIU/L) should be con-
sidered the therapeutic target” [18]. Subclinical hypothy-
roidism is generally characterized by a serum TSH level 
above the upper reference limit, combined with a normal 
FT4. This definition is applicable only when thyroid func-
tion has been stable for many weeks, there is a normal 
hypothalamic–pituitary–thyroid axis, and no recent or 
ongoing severe illness. Overt hypothyroidism is typically 
characterized by an elevated TSH (above 10  mIU/L) in 
combination with a subnormal FT4 [21].
In the appropriate clinical context, a subnormal serum 
FT4 level usually establishes the diagnosis of hypothy-
roidism, whether primary (elevated serum TSH) or cen-
tral (normal or low serum TSH) [22, 23]. The primary test 
for detecting hypothyroidism in patients with secondary 
hypothyroidism who are on a stable regimen of levothy-
roxine is a serum FT4 assessment. FT4 is also the primary 
measurement in patients who have been recently started 
on antithyroid drugs or have recently undergone surgical/
radioiodine ablation and were previously diagnosed as 
Table 1  Causes of treatment-refractory hypothyroidism
TSH thyroid-stimulating hormone [3–6, 8]
Decreased bioavailability
 Poor adherence to, or tolerability of, drug therapy
 Maldigestion due to patient-related factors or behavior
  Proton-pump inhibitor therapy
  Gastric infection with Helicobacter pylori
  Intestinal malabsorption of l-thyroxine
Luminal factors (e.g., food, coffee, and medications)
Intramural factors (e.g., short bowel syndrome, lactose intolerance, 
gluten enteropathy, inflammatory bowel disease, infiltrative enter-
opathy, infection with Giardia)
Increased need for levothyroxine
 Weight gain
 Pregnancy
 Increased metabolism of thyroxine
Other factors that can alter serum levels of TSH
 Addison’s disease
 Altered regulation of the hypothalamic-pituitary-thyroid axis
 TSH heterophile antibodies
 Inappropriate tablet storage
Table 2  Results from five published studies measuring TSH levels
a Inadequate thyroxine therapy: 18, 27, 18, 15, 28%; Excessive thyrox-
ine therapy: 14, 21, 22, 18, 14% [11–15]
Optimal thyroxine therapy 
(%)
Non-optimal 
 therapya (%)
Ross [11] 68 32
Parle [12] 52 48
Canaris [13] 60 40
Hollowell [14] 67 33
Vaisman [15] 58 42
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hyperthyroid based on low serum TSH levels over many 
weeks or months [21].
FT3 testing
As is the case with T4, T3 is also bound to serum proteins, 
principally T4-binding globulin (TBG), but to a lesser 
degree than T4. Methods for determining T3 concentra-
tion by direct immunoassay are currently in use [21, 24]. 
FT3 measurement has somewhat limited utility, however, 
in the diagnosis of hypothyroidism, since FT3 values often 
fall in the normal range as a result of hyperstimulation of 
the remaining functioning thyroid tissue by elevated TSH 
and to up-regulation of deiodinase D2, the enzyme that 
converts T4 to T3 [25]. In the absence of thyroid disease 
in severely ill patients, FT3 levels may be low because of 
reduced peripheral conversion of T4 to T3 and increased 
thyroid hormone inactivation [21, 26, 27].
TSH vs. FT3 testing
It is important to note that TSH is the most sensitive tar-
get gene of thyroid hormones. Even minimal changes in 
the content of thyroid hormones in the thyrotrophs can 
affect the synthesis of serum TSH and its secretion into 
the bloodstream. As reported by Taylor and colleagues 
[28], although a modest increase in the content of T4 (and 
T4-derived T3) found in the thyrotrophs will usually cause 
a substantial reduction in serum TSH in the setting of hypo-
thyroidism, the same modest level of increase in peripheral 
tissues (liver, muscles, etc.) does not cause appreciable 
changes in target genes. Clinically speaking, a decline in 
serum TSH to normal levels (pituitary euthyroidism) can, 
in theory, still coexist with tissue hypothyroidism in one or 
more target tissues. Residual hypothyroid symptoms may 
be a consequence of insufficient hormone levels in some 
peripheral tissues.
A lack of correlation between TSH and peripheral tis-
sue levels of T3 is worsened in conditions such as chronic 
emotional or physical stress, chronic illness, diabetes, insu-
lin resistance, obesity, leptin resistance, depression, chronic 
fatigue syndrome, fibromyalgia, premenstrual syndrome 
(PMS), and both dieting or weight gain. In such conditions, 
tissue levels of T3 are shown to drop dramatically out of 
proportion with serum T3 [29–37]. While serum T3 levels 
may decline by 30%, which is significant, but still within 
the so-called “normal range”, tissue T3 may decline by 
70–80%, resulting in profound cellular hypothyroidism 
with normal serum TSH, FT4, and FT3 levels [29–39]. As 
a result, TSH may be a poor indicator of peripheral thyroid 
levels in the presence of such conditions. In addition, a nor-
mal TSH should not always be considered a reliable indi-
cator for euthyreosis, especially in patients presenting with 
symptoms consistent with thyroid deficiency [40]. Several 
conditions such as age, pregnancy, and the presence of thy-
roid hormone antibodies may complicate the interpretation 
of TSH values [6, 8, 18]. In spite of these limitations, TSH 
remains the best means of assessing thyroid function in 
over 80% of patients.
Primary factors contributing to refractory 
hypothyroidism
In cases where TSH levels are unable to be maintained 
within a desired TSH range without the use of unexpect-
edly large daily doses of thyroxine therapy, clinicians 
should suspect the presence of one or more common con-
ditions that can make patients refractory to the traditional 
thyroid hormone treatment.
Non‑pathologic causes of refractory hypothyroidism
1. Non-compliance For many years, poor compliance 
with the daily dosing of levothyroxine was reputed to 
be the most common reason for unusually high doses 
of thyroid replacement therapy [1]. Because of its long 
half-life, missing 1 day of levothyroxine therapy has an 
influence on thyroid hormone and TSH levels that can 
extend for several days [41].
 The problem of non-compliance with thyroxine ther-
apy has traditionally been viewed within the context 
of missed doses of therapy. However, in the recently 
published CONTROL Surveillance Project among 
925 patients on levothyroxine therapy, McMillan et al. 
reported that many patients do not take thyroxine 
therapy as indicated. More than 21% reported taking 
thyroxine less than the recommended 30  min before 
eating, a practice that may significantly contribute to 
less-than-optimal drug absorption [42].
2. Switching to a generic levothyroxine with different bio-
availability Despite considerable efforts and progress 
by the healthcare community and regulatory bodies, 
concerns over levothyroxine substitution persist. Inter-
change of levothyroxine preparations at the pharmacy 
has been shown to contribute to sub-optimal manage-
ment of hypothyroidism. In 2010, the American Asso-
ciation of Clinical Endocrinologists (AACE), Ameri-
can Thyroid Association (ATA), and The Endocrine 
Society (TES) collaborated to conduct a survey of their 
society members and frequent prescribers of levothy-
roxine. From more than 18,000 emailed requests for 
information, the investigators found that the clinical 
use of contemporary levothyroxine products continues 
to be associated with adverse outcomes. The adverse 
outcomes most frequently reported were those asso-
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ciated with the generic substitution of levothyroxine 
products, frequently without the knowledge of the 
prescribing physician. Most of the cases resulted in 
either mild symptoms of hypo-or hyperthyroidism and/
or unexpected thyroid function tests that were outside 
normal limits [43].
3. Drugs that treat GI conditions/dietary considerations 
In tablet formulations, levothyroxine is absorbed pri-
marily at the jejunum and upper ileum. Several non-
pathologic factors that have been shown to affect lev-
othyroxine absorption and performance include diet 
(timing of ingestion relative to meals and beverages, 
including coffee), and use of certain nutritional sup-
plements, vitamins (including vitamin D), and medi-
cations such as proton-pump inhibitors (PPIs), hista-
mine receptor blockers, cholestyramine, and motility 
modifying agents. Sensitivity to ingredients contained 
in medication, poor tolerability, and, occasionally, 
improper storage of tablets have been shown to con-
tribute to levothyroxine malabsorption (Table 1) [3, 8, 
44–59].
 In the CONTROL Surveillance Project, McMillan 
et  al. documented the prevalence of factors that can 
affect the absorption and tolerability of levothyroxine. 
These included the presence of comorbid conditions 
such as gastroesophageal reflux disease (33.8%), irri-
table bowel syndrome (IBS) (9.7%), lactose intolerance 
(7.8%), or the use of prescription and OTC medica-
tions used to treat these conditions (34%). The use of 
dietary supplements (most notably iron and calcium) 
was reported in almost 52% of patients. Intake of foods 
and beverages high in fiber, iodine, or soy was reported 
in 68% of patients. More than 15% of patients reported 
allergies to ingredients that are known to be included in 
most tablet drug formulations [42].
4. Pregnancy Among patients undergoing body mass 
changes in the context of pregnancy, additional fac-
tors need to be considered. Alexander et  al. prospec-
tively studied 20 pregnant women with treated hypo-
thyroidism. Early in the first trimester, the investigators 
noted an increased levothyroxine requirement of up to 
50%, which peaked midway through pregnancy and 
remained constant until delivery [60]. Women with 
treated hypothyroidism, accordingly, may need to 
increase their dose of levothyroxine to prevent hypo-
thyroidism and its attendant adverse outcomes for 
pregnancy [61]. A pregnancy test should be considered 
for women of reproductive age suspected of having 
treatment-refractory hypothyroidism.
 The most recent ATA guidelines provide the follow-
ing trimester-specific reference ranges for TSH: “The 
treatment of hypothyroidism during pregnancy must 
be considered within the context of trimester-specific 
alterations in thyroid physiology as well as the etiol-
ogy of the thyroid disease. The TSH range for each tri-
mester should be defined within the medical system in 
which care is being provided, with a generalized range 
as follows: 0.1–2.5 mIU/L for the first trimester, 0.2–
3.0 mIU/L for the second trimester, and 0.3–3.0 mIU/L 
for the third trimester” [18].
Pathologic causes of refractory hypothyroidism
1. Concomitant GI diseases Possibly misunderstood in 
the past, or even confused with pseudomalabsorption 
[62], malabsorption of levothyroxine is now widely 
recognized as a legitimate medical problem in a sig-
nificant percentage of hypothyroid patients. Levo-
thyroxine absorption can be limited by a number of 
diseases of the gastrointestinal (GI) tract, including: 
Helicobacter pylori infection, inflammatory bowel dis-
ease (IBD), celiac disease, lactose intolerance, atrophic 
body gastritis (ABG), gastric bypass, biliary pancreatic 
diversion, and gastroparesis, among others [5, 10, 17, 
52, 63]. The presence of any of these conditions may 
adversely affect the absorption of levothyroxine and its 
dose requirements [3, 9, 17, 47, 49, 53, 54, 57, 64–70]. 
Collectively, these widespread disorders represent the 
most important causes of increased need for thyroxine.
2. Changes in body weight/body mass An important fac-
tor contributing to increased demand of levothyrox-
ine is weight change. Although the total daily dose 
of levothyroxine is usually higher in individuals who 
are obese, the dose per kilogram tends to be lower. 
In a case series of 75 consecutive post-thyroidectomy 
patients, an inverse relationship between the dose of 
levothyroxine required to normalize TSH levels and 
body weight was reported [71]. In a prospective study 
involving 100 post-thyroidectomy patients, the opti-
mal dose of levothyroxine (µg) could be predicted 
using a simple formula: dose  =  weight (kg)  −  age 
(years)  +  125 [72]. It is important to note that lean 
body mass is a better standard to gauge thyroxine 
requirements than weight.
 Rapid weight loss due to serious illness (e.g., certain 
malignancies, AIDS, malnutrition, and bariatric sur-
gery) has also been associated with oral levothyroxine 
homeostasis [73].
3. Poor conversion of T4 to T3 It has been suggested that 
a genetic variation in deiodinase D2 (also called type 
2 deiodinase, or 5′-deiodinase) may help to explain 
why some patients who fail to achieve control of 
hypothyroidism with a background of levothyroxine 
therapy respond to natural desiccated thyroid or to 
the combined therapy of levothyroxine and synthetic 
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T3 [74]. In a 2011 study, Gullo et  al. concluded that 
while the long-term effects of chronic tissue exposure 
to an abnormal T3/T4 ratio are not known, a sensitive 
marker of target organ response to thyroid hormones 
(i.e., serum TSH), suggests that the need for combi-
nation T3/T4 therapy may stem from abnormal pitui-
tary response. Thus, some patients may require a more 
“physiological” treatment than levothyroxine mono-
therapy [75].
 Kim and Bianco [76] postulated that some thyroid 
patients have a less effective deiodinase D2 enzyme for 
the conversion of T4 to T3. The authors suggest that 
this alteration occurs in 16% of the “poor converters” 
studied, and conclude that the majority of hypothy-
roid patients do not have this problem and can achieve 
the desired therapeutic response on T4 monotherapy. 
Bowthorpe et  al. have suggested that these “poor 
absorbers” need combined therapy of T4 and T3 [74]. 
However, the benefits of that treatment remain contro-
versial [77, 78].
Less common causes of refractory hypothyroidism
Other causes of treatment-refractory hypothyroidism are 
usually more difficult to identify. These include dysfunc-
tion in the hypothalamic–pituitary–thyroid axis (resistance 
to thyroid hormone) and Addison’s disease [8]. Benvenga 
and others have reported the occurrence of hypothyroidism 
due to levothyroxine malabsorption in patients with cystic 
fibrosis [9, 79–81]. Cystic fibrosis can be complicated by 
amyloidosis [82, 83] that can have a direct effect on the 
thyroid [9, 84]. In 2009, Morris discussed nephrotic syn-
drome as another potential cause of elevated TSH levels 
[41, 85–87]. Patients with autoimmune thyroid disease may 
be at higher risk of developing resistance to the traditional 
thyroid hormone replacement therapy. In a recent study, 
Yamamoto et  al. demonstrated the prevalence of anti-thy-
roxine antibodies among 187 patients with autoimmune 
thyroid diseases. Among those patients, such antibodies 
were discovered in 17.1% of patients (32/187) vs. 3.4% of 
patients (2/58) with non-autoimmune thyroid diseases [88].
Unknown reasons for refractory hypothyroidism
Suzuki and colleagues reported failure to identify a cause 
in approximately 10–20% of patients requiring greater than 
standard replacement doses of levothyroxine despite an 
extensive diagnostic work-up. Such patients have always 
existed [89]. Benvenga and Centanni have also reported 
rates of 10–20% for apparent idiopathic refractory hypothy-
roidism [9]. Hays described “thyroid-resistant” patients in 
a paper published in 1968. In that early study, Hays esti-
mated intestinal absorption of thyroxine from the serum 
125I/131I ratio after simultaneous administration of oral thy-
roxine-125I and intravenous thyroxine-131I. Hays character-
ized as “thyroid-resistant” four patients who were studied 
specifically because they appeared, clinically, to require, 
or at least tolerate, unusually high doses of thyroxine. All 
showed normal absorption percentages. Hays noted that 
the possibility that these patients may have had difficulty 
dissolving the usual tablet dosage forms of thyroxine was 
not likely. This study did show, however, that other patients 
with clinical malabsorption of food products do absorb thy-
roxine poorly. Whether or not this finding turns out to be 
clinically important, Hays further noted, remains to be seen 
[90].
These patients are frequently managed with parenteral 
administration of levothyroxine [9, 91–93]. Recently, a pos-
sible role for an altered intestinal microbiota composition 
has also been conceived [94, 95]. Our specific recommen-
dations for diagnosing and managing refractory hypothy-
roidism resulting from the wide range of etiologies dis-
cussed in this paper are presented below.
Discussion
As noted above, primary hypothyroidism is considered to 
be refractory to oral thyroxine when there is biochemical 
or clinical evidence of hypothyroidism (serum level of TSH 
above the upper target level, usually 4.5 mU/L following a 
6-week interval after the dosage was last increased) and/
or unresolved hypothyroid symptoms, despite increasing 
dosages beyond 1.9 μg/kg daily [1–3]. The most common 
approach to managing such patients is to escalate the dose 
of levothyroxine or change the levothyroxine formulation 
until target TSH levels are achieved and hypothyroid symp-
toms are controlled. However, due to the narrow therapeu-
tic index of levothyroxine, individualized dose titration can 
sometimes require considerable trial and error.
There are several drawbacks to this approach, including:
1. Effects on bone integrity Evidence in the clinical lit-
erature suggests that there is an increased risk of bone 
fracture in individuals who are exposed to suprath-
erapeutic doses of exogenous thyroid hormone for 
extended periods of time. According to Bauer et al. the 
risk of fracture is related to the degree of TSH suppres-
sion (TSH <0.1 mU/L vs. TSH 0.1–0.5 mU/L) in addi-
tion to other factors such as age [96]. In a recent obser-
vational cohort study that examined the risk of fracture 
in 17,684 patients >18 years old (mean age: 60.3 
females, 61.8 males) on long-term levothyroxine ther-
apy, a twofold increase in fracture risk was reported in 
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patients having undetectable TSH levels (≤0.03 mU/L) 
compared to those with TSH levels in the normal range 
[97]. More recently, Abrahamsen and colleagues found 
the long-term risk of hip and other osteoporotic frac-
tures among real-world patients to be strongly corre-
lated with the cumulative duration of periods with low 
TSH—most likely a consequence of excessive replace-
ment [98].
 While it is generally accepted that lengthy periods of 
hyperthyroidism affect bone mass density (BMD) and 
can increase the risk of osteoporosis, there is signifi-
cant controversy as to whether the long-term use of 
levothyroxine at suppressive or non-suppressive levels 
actually increases osteoporosis risk. Comprehensive, 
definitive research is required to establish with cer-
tainty whether suppressed or low-normal TSH levels 
increase the risk of osteoporosis and/or fractures, and 
whether the use of supplemental T3 has any effect at 
all on the risk of osteoporosis. The extent of such risk 
should also be assessed in comparison to the large 
number of other health risks (including the very real 
risk of heart disease) associated with elevated TSH lev-
els or physiologic hypothyroidism [99]. The first-line 
treatment of hypothyroidism dictates that thyroxine 
dosing be carefully monitored and adjusted as neces-
sary to prevent ongoing bone loss [100].
2. Cardiovascular and other effects Excessive thyroid 
hormone has been associated with an increase in car-
diovascular conditions such as tachycardia, left ven-
tricular hypertrophy, and poor diastolic relaxation. 
Such individuals are usually uncomfortable, and their 
pulse is high. Simply lowering the dose of levothyrox-
ine often solves the problem. Unfortunately, cardiac 
issues can develop, even in the absence of excessive 
thyroxine dosing in susceptible individuals [101]. In 
an observational cohort study, using data linkage from 
regional data sets between 1993 and 2001, Flynn and 
colleagues studied the safety of 17,684 patients with 
a low, but not suppressed, serum TSH when receiving 
long-term replacement therapy with levothyroxine. The 
researchers concluded that there was an increased risk 
of cardiovascular disease, dysrhythmias, and fractures 
in patients having high or suppressed TSH, but not in 
patients with low, but unsuppressed, TSH levels [97].
 As noted above, the potential consequences of supra-
therapeutic doses of levothyroxine are well known. 
As a result, many clinicians choose to start patients, 
especially those who may be at risk for ischemic heart 
disease, on low doses of levothyroxine and titrate up 
slowly until an ideal dose is achieved. Some patients 
are maintained permanently on sub-therapeutic or 
minimal doses of levothyroxine out of an abundance 
of concern. In our experience, this approach is flawed. 
Patients kept on sub-therapeutic doses of levothyroxine 
for long periods not only may suffer the classic symp-
toms of uncontrolled hypothyroidism, but may experi-
ence other significant physiologic effects. In a recent 
study, Piantanida et  al. demonstrated a correlation 
between uncontrolled hypothyroidism and increased 
risk for masked hypertension (MH). Masked hyperten-
sion, or the association of normal office blood pressure 
readings with high ambulatory or home measurements, 
is a significant risk factor for target organ damage. The 
authors concluded that restoration of euthyroidism via 
thyroid replacement therapy can help lower blood pres-
sure and cardiovascular risk among patients with MH 
[102]. Similar results were noted by Gallo et  al. in a 
study measuring neuromuscular symptoms in 57 newly 
diagnosed hypothyroid patients. Among those patients 
with overt hypothyroidism, there was a significantly 
higher prevalence of both neuromuscular symptoms 
(myalgias, slowness of movement, and tiredness) and 
elevated serum creatine phosphokinase (CPK) levels 
compared with euthyroid patients (P < 0.0001). After 
thyroid replacement therapy was initiated, normaliza-
tion of CPK levels and restoration of normal neuro-
muscular function were observed. The authors con-
cluded that thyroid hormone replacement therapy may 
be helpful in reversing abnormalities of physical per-
formance which may have a negative impact on patient 
well-being and quality of life [103].
3. Increased use of healthcare resources Dose titration of 
levothyroxine is common in clinical practice and can 
result in unnecessary use of healthcare and other soci-
etal resources. In CONTROL HE, a retrospective study 
of 454 patients receiving levothyroxine for greater than 
1  year, Ernst et  al. reported a significant relationship 
between the number of levothyroxine dose or formula-
tion changes and increased cost of patient care includ-
ing drug therapy, laboratory tests, physician visits, and 
other healthcare costs (P < 0.05). These dose changes 
were also associated with an increase in lost wages 
and work productivity. Patients with ≥1 levothyrox-
ine dose or formulation change in a 24-month period 
experienced an increase in total resource utilization 
of US $2658 versus patients who had not experienced 
changes to their levothyroxine therapy. Patients with 
≥3 levothyroxine dose changes in a 24-month period 
had costs that were 2.5 times greater than patients 
with no dose or formulation changes (US $8220 vs. 
US $3166). According to the authors, levothyroxine 
dose and formulation changes escalate the socioeco-
nomic burden of hypothyroidism care by both increas-
ing healthcare costs and decreasing work productivity 
[104].
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4. Patient satisfaction with therapy Levothyroxine dose 
and formulation changes can have an impact on patient 
satisfaction with care. In CONTROL TS, a survey 
involving 300 hypothyroid patients taking levothy-
roxine for more than 1 year, individuals reporting ≥2 
levothyroxine dose changes in the past 12 months were 
significantly less satisfied with their hypothyroid treat-
ment than those reporting no dose changes. Those 
patients were less likely to feel that their thyroid medi-
cation was controlling their hypothyroid symptoms and 
were less enthusiastic about continuing their current 
medication regimen. Overall patient satisfaction with 
treatment was 44% lower among patients experienc-
ing levothyroxine dose changes versus those without 
such changes (P  <  0.001). Patients whose levothy-
roxine therapy had been changed multiple times were 
also more likely to be dissatisfied with their hypothy-
roid care and more likely to have changed their hypo-
thyroid-treating physician in the past year: +66.1% 
(P = .054) [105].
Diagnosing and managing refractory 
hypothyroidism
Key principle
When confronted with patients in which escalating doses 
of thyroid replacement hormone have failed to control TSH 
levels and symptoms of hypothyroidism, clinicians should 
employ a systematic approach to gathering information and 
determining an effective therapeutic strategy. We recom-
mend the following eight-step approach, which has been 
validated through empirical use and should be considered 
as an alternative to the standard practice of escalating doses 
of levothyroxine:
1. Confirm the diagnosis and laboratory results By 
laboratory definition, frank primary hypothyroidism 
requires low levels of thyroid hormones (free–FT4 and 
FT3) as well as elevated TSH. The finding of persis-
tently elevated TSH is insufficient to confirm the diag-
nosis—it is also essential to measure thyroid hormone 
levels (FT4 and FT3). Markedly elevated TSH levels 
in the absence of low or at least low-normal thyroid 
hormones suggest other diagnoses or explanations for 
the increased dose requirements (e.g., heterophilic anti-
body interference with TSH measurements) [41]. It is 
important to remember that TSH levels are best inter-
preted in light of each patient’s clinical history (famil-
ial, pharmacological, surgical, other morbidities, etc.)
2. Ask about compliance Poor compliance is the most 
common reason for unusually high thyroid hormone 
dose requirements. Patients will often acknowledge 
occasionally forgetting their levothyroxine tablets if 
asked in a non-accusatory, non-judgmental manner. 
What can be difficult is determining how often ‘occa-
sionally’ actually occurs [41]. If necessary, clinicians 
can investigate adherence to therapy by direct patient 
report, clinical impression, or frequency of pharmacy 
refills. A supervised test for levothyroxine absorption 
may be useful if poor adherence to oral treatment is 
suspected [8, 106, 107].
3. Check the patient’s medication bottles and tablets The 
patient’s reported dose may, at times, differ from that 
prescribed, and pharmacy errors can also occur, result-
ing in tablets inside the bottle that are not the same as 
those reported on the label [41]. In difficult-to-con-
trol hypothyroid patients, the panel also recommends 
checking for appropriate storage of levothyroxine tab-
lets (e.g., protection from light, moisture, and tempera-
ture extremes, as stated in the package insert) [108].
4. Review the thyroxine ingestion history The most effi-
cient way to take levothyroxine—and the most repro-
ducible—is to ingest the tablets on an empty stomach 
and avoid other medications or food for 30–60  min 
(preferably 60) thereafter [4, 5, 48]. As noted above, 
a large and growing number of medications, supple-
ments, and food items have been shown to alter the 
fraction of an ingested dose that is absorbed [109, 
110]. The ingestion of one or more of these at, or close 
to, the time of levothyroxine dosing can significantly 
change the dose requirement in individual patients, 
especially when done regularly [49].
5. Investigate for levothyroxine malabsorption Inter-indi-
vidual variability in the efficiency of GI absorption is 
rather large, and such variability accounts for most of 
the range of dose requirements seen among compliant 
patients following adjustment for body size. The first 
sign of malabsorption syndrome, which is frequently 
oligosymptomatic and previously undiagnosed, can be 
the need for unexpectedly high doses of levothyroxine 
in replacement therapy. Individuals taking levothyrox-
ine in daily doses exceeding 1.9  μg/kg body weight, 
and who have persistently elevated TSH levels and/or 
unresolved symptoms of hypothyroidism, should be 
evaluated, and, if indicated, undergo testing for mal-
absorption. We are recommending a diagnostic flow 
chart (Fig.  1), which, based on increased thyroxine 
requirements [10], can help to establish the presence of 
concomitant GI disorders [111–113]. Frequently, cor-
rection of the malabsorption will normalize, or at least 
improve, levothyroxine absorption in patients with 
these disorders [10].
6. Consider increased turnover or excretion Several 
drugs or clinical conditions can increase the turnover 
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or excretion of thyroid hormone, thereby substantially 
increasing the requirement in patients who are thyroid 
hormone dependent. These medications include pheny-
toin, carbamazepine, and rifampin. A number of kinase 
inhibitors, including imatinib and sunitinib, appear 
to influence thyroxine requirements through what is 
likely a class effect [114–116]. Moreover, patients 
with nephrotic syndrome who excrete large quantities 
of albumin may also have increased thyroxine require-
ments as a result of the binding of levothyroxine to the 
excreted albumin [87]. As mentioned above, during 
normal pregnancy, women experience increased thy-
roxine requirements that may approach 50% [41, 60].
• Perform a thyroxine absorption test Although not 
standardized, a clinical test for estimating the absorp-
tion of thyroxine may have utility in some patients 
who have unexpectedly high thyroxine requirements. 
The absorption test involves administration of a sin-
gle large dose of levothyroxine, typically in the range 
of 600–1000  μg, followed by monitoring serum 
thyroxine levels over time [110]. Using a high-dose 
levothyroxine, absorption test can play an important 
role in the differential diagnosis of pseudomalab-
sorption (which is a most common source of difficul-
ties in obtaining euthyreosis in hypothyroid patients) 
and actual levothyroxine malabsorption [117, 118]. 
Because it is not standardized, and unlikely to be 
associated with a specific etiology, the absorption 
test should not be used routinely [9, 41, 51].
• Treat the patient holistically If a mistake by the 
patient or a pharmacy-related cause is identified, 
correction of these factors may resolve the problem. 
In some situations, compliance issues can be treated 
best by increasing the size of the tablet. As a last 
resort in those with continuing poor compliance, 
administration of thyroxine once weekly can be suc-
cessful [119]. When possible, removing interfering 
drugs (such as PPIs) or changing ingestion patterns 
can also be helpful. In select patients, weight control 
can be an important step in the right direction. Such 
individualized treatment can improve the overall cost 
of care.
Alternative levothyroxine formulations
Another approach that may be considered is to try alterna-
tive formulations of levothyroxine that are less susceptible 
to intolerance or malabsorption. Two novel formulations of 
levothyroxine sodium are now available, a softgel and a liq-
uid. The efficacy and tolerability of these alternative formu-
lations of levothyroxine have recently been reported in the 
scientific literature [120].
In particular, Santaguida et  al. [121] have shown that 
most patients with definite gastric disorders benefited by 
changing from the traditional tablet formulations to the 
softgel levothyroxine preparation at a reduced dose. CON-
TROL Switch, a recent retrospective study involving 99 
hypothyroid patients being treated by endocrinologists, 
suggested that a strategy of switching therapy from the tra-
ditional levothyroxine tablets to levothyroxine gel caps may 
preclude or reduce the need for levothyroxine dose or for-
mulation changes, while improving hypothyroid symptom 
Fig. 1  Diagnostic flow chart of 
thyroxine malabsorption. + if 
test is positive, − if test is nega-
tive. EMA endomysial antibody. 
(Modified from Centanni M, 
hotthyroidology.com 2007)
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control, in some patients [122]. In that study, switching pri-
marily from either branded or generic levothyroxine tablets 
to levothyroxine gel caps resulted in:
• Significant reduction in dose adjustments; −55% 
(P  <  0.0001). More than 85% of patients experienced 
≤1 dose adjustment post-switch.
• Significant improvement in hypothyroid symptom con-
trol; +62% (P < 0.0001). Among patients switched for 
efficacy reasons (n  =  25), 64% experienced improved 
symptom control.
As far as it concerns the liquid formulation, Fallahi et al. 
studied the effect of switching 152 patients from levothy-
roxine tablets to a liquid formulation of levothyroxine. 
Unlike prior studies that evaluated the switch of patients 
from tablets to a gel cap formulation, this study evalu-
ated the effects of switching patients with no prior history 
of levothyroxine malabsorption, gastric disorders, or use 
of drugs that are known to interfere with levothyroxine 
absorption. Serum TSH, FT4, and FT3 were evaluated after 
1–3 months (first control) and 5–7 months (second control) 
after the medication switch. Following the switch to the liq-
uid formulation, TSH levels among patients significantly 
declined compared to the basal value at both the first con-
trol (P < 0.05) and the second control (P < 0.01). Levels 
of both FT4 and FT3 were not significantly changed [123].
In the end, the decision to use an alternative formula-
tion of levothyroxine may be one of expediency. Recent 
evidence suggests that either the softgel or liquid alterna-
tives may eliminate a number of factors that contribute to 
levothyroxine tablet failure and refractory hypothyroidism. 
They may also offer options to patients who are non-com-
pliant, have difficulty swallowing medication, or decline 
treatment because of sensitivity to excipients commonly 
contained in most commercially available tablet formula-
tions. Patients with impaired gastric pH and those with sen-
sitivity to excipients found in the traditional levothyroxine 
tablets can stand to benefit from these alternative options.
Conclusions
There is a frequently encountered subset of hypothy-
roid patients who are refractory to standard thyroid hor-
mone replacement treatment and require unexpectedly 
high doses of levothyroxine or who have erratic control 
of hypothyroidism, alternating between over-replacement 
and under-replacement. In addition to clinical situations 
where hypothyroid patients are non-compliant, or where 
there is the possibility of excipient-induced disease exac-
erbation (gluten/celiac disease), therapeutic failure may be 
due to impaired absorption of the administered drug. This 
is often the result of either patient pathophysiology (GI dis-
ease), the effects of other therapeutic agents, or diet (tim-
ing of ingestion relative to meals and beverages, includ-
ing coffee). Significant swings in weight may also cause 
treatment-refractory hypothyroidism. Switching to generic 
levothyroxine products has also been correlated with sub-
optimal outcomes.
The common approach to managing patients with unu-
sual thyroxine needs is to escalate the dose of levothyrox-
ine until targeted TSH levels are achieved. This approach 
can increase the risk for prolonged exposure to suprathera-
peutic doses of levothyroxine which increase the chances 
of adverse outcomes. Studies have demonstrated that even 
intermittent oversuppression of TSH using levothyroxine 
can result in increased bone loss, cardiovascular, and other 
more serious medical conditions [97, 99, 101]. Repeated 
adjustments of levothyroxine can also escalate the costs of 
treatment, as frequent office visits and lab tests are required 
to determine and maintain the desired dose. These can also 
reduce patient satisfaction with hypothyroid treatment.
In our view, clinicians should take a systematic approach 
to managing patients whom they suspect of having treat-
ment-refractory hypothyroidism. This may include search-
ing for occult medical conditions, or other factors that may 
affect the absorption of levothyroxine, before up-titrating 
the dose of the traditional levothyroxine therapy. Depend-
ing on the underlying pathology, another approach that may 
be considered is to try alternative formulations of levothy-
roxine that are less susceptible to tolerance issues related to 
excipients or, in some cases, to malabsorption. In all cases, 
we advocate that the eight-step algorithm presented be used 
to carefully assess patient needs before treatment choices 
are made; such a strategy offers an alternative to reduc-
tionism as stated by Trimarchi in 2015 [124]. This holistic 
approach acknowledges that treatment-refractory hypothy-
roidism is a condition that exists within the context of other 
important factors—GI disease, concomitant drug use, diet, 
and patient habits—whose presence may adversely affect 
thyroid replacement therapy. The early discovery of these 
factors via a thoughtful patient work-up may avoid unnec-
essary thyroid medication adjustments and their conse-
quences for patients, clinicians, and the healthcare system.
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